Regulus Therapeutics Inc.

NasdaqCM RGLS

Regulus Therapeutics Inc. Free Cash Flow Yield on February 03, 2025

Regulus Therapeutics Inc. Free Cash Flow Yield is NA on February 03, 2025, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Regulus Therapeutics Inc. 52-week high Free Cash Flow Yield is -15.64% on April 12, 2024, which is NA below the current Free Cash Flow Yield.
Regulus Therapeutics Inc. 52-week low Free Cash Flow Yield is -73.24% on February 06, 2024, which is NA below the current Free Cash Flow Yield.
Regulus Therapeutics Inc. average Free Cash Flow Yield for the last 52 weeks is -33.56%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: RGLS

Regulus Therapeutics Inc.

CEO	Mr. Joseph P. Hagan M.B.A.
IPO Date	Oct. 9, 2012
Location	United States
Headquarters	4224 Campus Point Court
Employees	32
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Key trends

Past 5 years